SCHEMBL14639476

SCHEMBL14639476

O=C(OCc1ccccc1)N1CC(C2=C3C=NC=C[N+]3(Cl)C(Br)=N2)CCC1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK3 Q15120 1/20 0.36
PDK4 Q16654 1/20 0.36
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
AGTR2 P50052 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
PREP P48147 1/20 0.32
CYP2C19 P33261 1/20 0.31
F2 P00734 2/20 0.31
ELANE P08246 2/20 0.31
CTSG P08311 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14636243 0.84 PDK1 (0.35) PDK1PDK2PDK3PDK4PSEN1
SCHEMBL15878121 0.80 F2 (0.34) AGTR2SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL15878608 0.79 PREP (0.38) PREP
SCHEMBL14637752 0.78 ALDH1A1 (0.39)
SCHEMBL15903027 0.74 PREP (0.35) SMN1; SMN2NPC1RAB9APREPCYP2C19
SCHEMBL594302 0.72 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL2327202 0.71 JAK2 (0.40) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL14630463 0.70 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL2322567 0.70 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL14637260 0.70 SIGMAR1 (0.44) PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2734529-B1 BTK INHIBITORS MERCK SHARP & DOHME (US) 2018-09-05 EP disclosed
US-9718828-B2 BTK Inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-01 US disclosed
US-20170008899-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-20140221333-A1 BTK INHIBITORS MERCK SHARP & DOHME B.V. (NL) 2014-08-07 US disclosed
EP-2734529-A1 BTK INHIBITORS Merck Sharp & Dohme Corp. (US) 2014-05-28 EP disclosed
WO-2013010380-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008899-A1 BTK INHIBITORS BTK, SYK, ABL1 PDK1 714/4885PDK2 1188/4885PDK3 1869/4885
US-20140221333-A1 BTK INHIBITORS BTK, SYK, ABL1 PDK1 675/4885PDK2 1180/4885PDK3 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.